STAT+: Fatal gene-editing trial in China raises ethics and oversight questions

Also Read

• Healthcare Investors Pivot to Revenue-Driven AI Strategies as Traditional Cost-Cutting Yields Diminishing Returns
• Male Nurses Now Account for One‑Eighth of the U.S. Nursing Workforce, Growth Focused on Shortage Regions
• AHRQ Terminates Funding for Dozens of Health Research Projects
• Louisiana Senator Supports Trump Nominee for C.D.C. Director Amid Vaccine Autism Website Revamp